

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

Assignment ID: PATI666158

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Release of Security Interests

**CONVEYING PARTY DATA**

Name	Execution Date
Acquiom Agency Services, LLC, as Collateral Agent	11/29/2024

**RECEIVING PARTY DATA**

<b>Company Name:</b>	Mallinckrodt Pharma IP Trading Limited
<b>Street Address:</b>	College Business & Technology Park Cruiserath
<b>City:</b>	Blanchardstown, Dublin
<b>State/Country:</b>	IRELAND
<b>Postal Code:</b>	15
<b>Company Name:</b>	Stratatech Corporation
<b>Street Address:</b>	510 Charmany Dr # 169
<b>City:</b>	Madison
<b>State/Country:</b>	WISCONSIN
<b>Postal Code:</b>	53719
<b>Company Name:</b>	Mallinckrodt Pharmaceuticals Ireland Limited
<b>Street Address:</b>	College Business & Technology Park Cruiserath
<b>City:</b>	Blanchardstown, Dublin
<b>State/Country:</b>	IRELAND
<b>Postal Code:</b>	15

**PROPERTY NUMBERS Total: 25**

Property Type	Number
Patent Number:	7186230
Patent Number:	7479123
Patent Number:	7850634
Patent Number:	7914477
Patent Number:	11186823
Patent Number:	10926020
Patent Number:	10940259
Patent Number:	10953149
Patent Number:	11124767
Patent Number:	9169461

**PATENT**

Property Type	Number
Patent Number:	10138464
Patent Number:	7476209
Patent Number:	8057785
Patent Number:	8481008
Patent Number:	10434239
Patent Number:	11020522
Patent Number:	10641415
Patent Number:	10828415
Application Number:	17547966
Application Number:	17458206
Application Number:	16906976
Application Number:	17176013
Application Number:	18103202
Application Number:	18200137
Application Number:	17787836

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2025218721

**Email:** ipteam@coagencyglobal.com

**Correspondent Name:** Troy Jones

**Address Line 1:** 1025 Connecticut Ave NW, Suite 712

**Address Line 2:** Cogency Global Inc.

**Address Line 4:** Washington, DISTRICT OF COLUMBIA 20036

<b>NAME OF SUBMITTER:</b>	Andrew Hackett
<b>SIGNATURE:</b>	Andrew Hackett
<b>DATE SIGNED:</b>	12/03/2024

**Total Attachments: 5**

source=Project Maverick - Partial Release of Patent Security Interests [Executed]#page1.tiff

source=Project Maverick - Partial Release of Patent Security Interests [Executed]#page2.tiff

source=Project Maverick - Partial Release of Patent Security Interests [Executed]#page3.tiff

source=Project Maverick - Partial Release of Patent Security Interests [Executed]#page4.tiff

source=Project Maverick - Partial Release of Patent Security Interests [Executed]#page5.tiff

PARTIAL RELEASE OF PATENT SECURITY INTERESTS dated as of November 29, 2024 (this “Partial Release”), by Acquiom Agency Services, LLC, as Collateral Agent (the “Collateral Agent”), in favor of Mallinckrodt Pharmaceuticals Ireland Limited, a private limited company incorporated under the laws of Ireland, Mallinckrodt Pharma IP Trading Limited, a limited company incorporated under the laws of Ireland (as successor to Mallinckrodt Hospital Products IP Limited), and Stratatech Corporation, a Delaware corporation (each, a “Company”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Credit Agreement, Indenture or Collateral Agreement (each as defined below), as applicable.

A. Reference is made to the (i) Credit Agreement, dated as of November 14, 2023 (as amended, restated, supplemented, otherwise modified, refinanced or replaced from time to time, the “Credit Agreement”), among Mallinckrodt plc, a public limited company incorporated under the laws of Ireland with registered number 522227 (the “Parent”), Mallinckrodt International Finance S.A., a public limited liability company (*société anonyme*) incorporated under the laws of the Grand Duchy of Luxembourg (the “Lux Borrower”), Mallinckrodt CB LLC, a Delaware limited liability company (the “Co-Borrower”, and together with the Lux Borrower, the “Borrowers”), the Lenders from time to time party thereto, Acquiom Agency Services LLC and Seaport Loan Products LLC, each a Co-Administrative Agent and the Collateral Agent, (ii) Indenture, dated as of November 14, 2023 (as amended, supplemented, restated or otherwise modified from time to time, the “Indenture”), among the Borrowers, as Issuer and Co-Issuer, Parent, the other Guarantors party thereto from time to time, Wilmington Savings Fund Society FSB, as First Lien Trustee and the Collateral Agent; (iii) U.S. Collateral Agreement, dated as of November 14, 2023 (as amended, supplemented, restated or otherwise modified from time to time, the “Collateral Agreement”), among the Borrowers, the other Pledgors party thereto from time to time and the Collateral Agent, (iv) Notice of Grant of Security Interest in Patents, dated as of November 14, 2023 (the “2023 Patent Security Agreement”), among the Pledgors listed therein and the Collateral Agent and (v) Notice of Grant of Security Interest in Patents, dated as of April 24, 2024 (the “2024 Patent Security Agreement”, and together with the 2023 Patent Security Agreement, the “Patent Security Agreements”), among the Pledgors listed therein and the Collateral Agent.

B. Pursuant to the Collateral Agreement and the Patent Security Agreements, each Company assigned and pledged to the Collateral Agent (and its successors and permitted assigns), for the benefit of the Secured Parties, a continuing security interest in all of such Company’s right, title and interest in, to and under, among other things, such Company’s Patents set forth on Schedule I hereto (the “Released Patent Collateral”), which security interests were recorded with the United States Patent and Trademark Office on (i) November 15, 2023 at Reel/Frame No. 065595/0376 and (ii) April 24, 2024 at Reel/Frame No. 067215/0426.

C. Each Company has requested that the Collateral Agent execute and deliver this Partial Release to evidence the release of its security interest in the Released Patent Collateral for filing and recordation with the United States Patent and Trademark Office.

D. Pursuant to Section 9.18 of the Credit Agreement, Section 13.02 of the Indenture and the corresponding provisions of the Collateral Agreement and the other Loan

Documents and the Note Documents, the Collateral Agent does hereby agree to evidence the release of any and all security interests it may have against the Released Patent Collateral, and hereby reassigns to each Company, as applicable, any and all right, title and interest that the Collateral Agent may have in, to or under the Released Patent Collateral, provided, however, that this release is being made without recourse to, or any representation or warranty by, the Collateral Agent.

E. Immediately and automatically upon the Closing (as defined in the Purchase and Sale Agreement, dated as of August 3, 2024 (as amended by Amendment No. 1 to the Purchase and Sale Agreement, dated as of November 29, 2024), by and between Parent, Solaris Bidco Limited, an Irish private company limited by shares, Solaris IPCo Limited, an Irish private company limited by shares, and Solaris US Bidco, LLC, a Delaware limited liability company) and without any further action by any party, all security interests, pledges, mortgages, encumbrances and other Liens, of any kind, nature or description, in the Released Patent Collateral, granted under the Collateral Agreement and the Patent Security Agreements, are irrevocably discharged, terminated and released.

F. This Partial Release is applicable only and solely with respect to the Released Patent Collateral and to no other Collateral arising under the Collateral Agreement or the Patent Security Agreements (such collateral, the “Retained Collateral”). The Collateral Agent retains all security interests, Liens, rights, titles and interests pledged and granted to it under the Collateral Agreement and the Patent Security Agreements with respect to all Retained Collateral, and the Collateral Agent’s security interests, Liens, rights, titles and interests in the Retained Collateral shall not, and shall not be deemed to, be impaired, interrupted or otherwise modified in any respect by this Partial Release. Except as expressly modified hereby, the Collateral Agreement or the Patent Security Agreements shall remain in full force and effect.

**THIS PARTIAL RELEASE SHALL BE GOVERNED BY AND CONSTRUED  
IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.**

[Signature page follows]

IN WITNESS WHEREOF, the Collateral Agent has caused this Partial Release to be duly executed as of the day and year first above written.

ACQUIOM AGENCY SERVICES, LLC, as  
Collateral Agent

By:   
Name: Beth Cesari  
Title: Exec Director

SCHEDULE I  
to  
PARTIAL RELEASE OF PATENT SECURITY INTERESTS

Released Patent Collateral

Reel/Frame: 065595/0376

Country	Invention Title	Appl. No.	Filing Date	Patent No.	Issue Date	Status	Owner
United States of America	METHODS TO PRODUCE HIGHLY IMMATURE MONOCYTE DERIVED DENDRITIC CELLS	17/547966	10-Dec-2021			Pending	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	METHOD AND APPARATUS FOR THE CONTINUOUS SEPARATION OF BIOLOGICAL FLUIDS INTO COMPONENTS	10/375629	27-Feb-2003	7186230	06-Mar-2007	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED / MALLINCKRODT PHARMA IP TRADING LIMITED (as successor to MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED)
United States of America	METHOD FOR COLLECTING A DESIRED BLOOD COMPONENT AND PERFORMING A PHOTOPHERESIS TREATMENT	10/654803	03-Sep-2003	7479123	20-Jan-2009	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	METHOD FOR COLLECTING A DESIRED BLOOD COMPONENT AND PERFORMING A PHOTOPHERESIS TREATMENT METHOD	11/613021	19-Dec-2006	7850634	14-Dec-2010	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	APPARATUS FOR THE CONTINUOUS SEPARATION OF BIOLOGICAL FLUIDS INTO COMPONENTS AND METHOD OF USING SAME	11/406988	19-Apr-2006	7914477	29-Mar-2011	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASES	15/981332	16-May-2018	11186823	30-Nov-2021	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	PROCESSING BLOOD	15/974881	09-May-2018	10976020	23-Feb-2021	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	PROCESSING BLOOD	16/171089	25-Oct-2018	10940259	09-Mar-2021	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	PROCESSING BLOOD	16/171096	25-Oct-2018	10953149	23-Mar-2021	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS	16/165679	19-Oct-2018	11124767	21-Sep-2021	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS	11/579319	14-Jul-2008	9169461	27-Oct-2015	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS	14/863274	23-Sep-2015	10138464	27-Nov-2018	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	METHOD AND APPARATUS FOR COLLECTING A BLOOD COMPONENT AND PERFORMING A PHOTOPHERESIS TREATMENT	11/304092	15-Dec-2005	7476209	13-Jan-2009	Granted	MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED

Country	Invention Title	Appl. No.	Filing Date	Patent No.	Issue Date	Status	Owner
United States of America	PHOTOTHERAPY COMPOSITIONS AND METHODS	11/311714	19-Dec-2005	8057785	15-Nov-2011	Granted	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	PHOTOTHERAPY COMPOSITIONS AND METHODS	13/243103	23-Sep-2011	8481008	09-Jul-2013	Granted	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	CENTRIFUGE SYSTEM AND METHOD WITH COMPONENT TRACKING	15/261968	11-Sep-2016	10434239	08-Oct-2019	Granted	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	CENTRIFUGE SYSTEM AND METHOD WITH COMPONENT TRACKING	16/537103	09-Aug-2019	11020522	01-Jun-2021	Granted	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	SUPPORT FOR CENTRIFUGE TUBING	15/570996	31-Oct-2017	10641415	05-May-2020	Granted	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	DEVICES, METHODS AND SYSTEMS FOR PRIMING, SEPARATING, AND COLLECTING BLOOD COMPONENTS	15/737163	15-Dec-2017	10828415	10-Nov-2020	Granted	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS	17/458206	26-Aug-2021			Published	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	DEVICES, METHODS AND SYSTEMS FOR PRIMING, SEPARATING, AND COLLECTING BLOOD COMPONENTS	16/906976	19-Jun-2020			Pending	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	PROCESSING BLOOD	17/176013	15-Feb-2021			Published	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	METHOD OF EXTRACORPOREAL PHOTOPHERESIS FOR IMMUNE-RELATED ADVERSE EVENTS	18/103202	30-Jan-2023			Pending	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	METHODS TO PRODUCE HIGHLY IMMATURE MONOCYTE DERIVED DENDRITIC CELLS	18/200137	22-May-2023			Pending	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED
United States of America	METHOD FOR GENERATING IMMUNOREGULATORY CELLS IN A BLOOD-DERIVED SAMPLE	17/787836	21-Jun-2022			Published	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED / STRATAVECH CORPORATION

Reel/Frame: 067215/0426

Country	Invention Title	Appl. No.	Filing Date	Patent No.	Issue Date	Status	Owner
United States of America	METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASES	18/584070	2/22/2024			Pending	MALLINGKRODT PHARMACEUTICALS IRELAND LIMITED

PATENT

REEL: 069476 FRAME: 0109

RECORDED: 12/03/2024